Emergent BioSolutions Inc said the U.S. Food and Drug Administration approved its treatment for inhaled anthrax, triggering a $7 million milestone payment from the Department of Health and Human Services (HHS).
The company developed the treatment, Anthrasil, as part of a $160 million contract it signed in 2005 with the Biomedical Advanced Research and Development Authority (BARDA), a part of the HHS.
{iframe}http://www.reuters.com/article/2015/03/25/us-emergent-bio-fda-idUSKBN0ML16P20150325{/iframe}